Inefficiencies and Patient Burdens in the Development of the Targeted Cancer Drug Sorafenib: A Systematic Review
Fig 3
Accumulation of Evidence and Research Organization (AERO) diagram of sorafenib monotherapy trials, arranged by enrolment date.
Rectangular nodes indicate Phase I trials, circular nodes indicate Phase II trials, and triangular nodes indicate Phase III trials. Green nodes indicate studies that reached their primary endpoint with acceptable toxicity (positive trials), yellow nodes indicate an inconclusive study, and red nodes indicate a failure to reach the primary endpoint or unacceptable toxicity (negative trials). White nodes are trials with nonefficacy primary endpoints. Bold denotes FDA-approved indications and corresponding years of licensure. Numbers in nodes represent the reference numbers of each trial. Per-trial data are available in our supplementary materials (see S1 Data).
doi: https://doi.org/10.1371/journal.pbio.2000487.g003